Joseph M. Tuscano

United States Department of Veterans Affairs — United States

Medicine · Health Sciences

42h-index6.4kcitations310works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lymphoma Diagnosis and Treatment(137), Chronic Lymphocytic Leukemia Research(93), CAR-T cell therapy research(84), Multiple Myeloma Research and Treatments(32), Acute Myeloid Leukemia Research(29)

Publications310 total

Suppl Fig 2 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
2025Open Access
Suppl Fig 3 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
2025Open Access
Supplementary Data1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
2025Open Access
Suppl Fig 1 from Targeting the Inducible T-cell Costimulator (ICOS) in Patients with Relapsed/Refractory T-follicular Helper Phenotype Peripheral T-cell and Angioimmunoblastic T-cell Lymphoma
2025Open Access
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis
Blood Advances·2025· 1 citedOpen Access
Results of A phase I study of peposertib in combination with MEC in patients with relapsed or refractory Acute Myeloid Leukemia
Blood·2025Open Access
Pembrolizumab + GVD with ctdna-guided consolidation for relapsed/refractory classic Hodgkin lymphoma: A multicenter phase 2 Study of the University of California hematologic malignancies consortium
Blood·2025Open Access
Efficacy and safety of loncastuximab tesirine and rituximab (Lonca-R) followed by dose-adjusted rituximab with etoposide, doxorubicin, cyclophosphamide, vincristine and prednisone (DA-R-EPOCH) in previously untreated high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary results from a University of California Malignancy Consortium (UCHMC) Phase II trial, UCDCC#303.
Blood·2025Open Access
A Phase II trial of obinutuzumab, ibrutinib and venetoclax in patients with previously untreated follicular lymphoma; A University of California hematologic malignancies consortium study
Blood·2025Open Access
Somatic mutations and clinical outcomes in primary central nervous system lymphoma among hispanic and non-hispanic patients: A study from the University of California hematologic malignancies consortium (UCHMC)
Blood·2025Open Access
NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025
Journal of the National Comprehensive Cancer Network·2025· 1 cited
Intensified Cyclophosphamide, Bortezomib, Dexamethasone (iCyBorD) for the Treatment of Newly Diagnosed Multiple Myeloma with Acute Kidney Injury
Clinical Lymphoma Myeloma & Leukemia·2025
Lymphoma Therapy Response Assessment with Low-Dose [<sup>18</sup>F]FDG Total-Body PET/CT
Journal of Nuclear Medicine·2025· 2 citedOpen Access
Light chain crystalline podocytopathy caused by electron-lucent crystals – a diagnostic challenge: a case report
Ultrastructural Pathology·2025
Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826
Journal of Clinical Oncology·2025· 10 citedOpen Access
A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503)
Leukemia Research·2025· 1 cited
641 | OUTCOMES OF DOSE ADJUSTED R‐EPOCH IN ELDERLY PATIENTS: A RETROSPECTIVE STUDY
Hematological Oncology·2025Open Access
777 | INTENSIFIED CYCLOPHOSPHAMIDE, BORTEZOMIB, DEXAMETHASONE FOR THE TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA WITH ACUTE KIDNEY INJURY
Hematological Oncology·2025Open Access
228 | A UC HEMATOLOGIC MALIGNANCY CONSORTIUM PHASE II TRIAL OF OBINUTUZUMAB, IBRUTINIB AND VENETOCLAX IN PATIENTS WITH PREVIOUSLY UNTREATED FOLLICULAR LYMPHOMA
Hematological Oncology·2025Open Access
A Phase I Study of CD19 CAR T-Cells with Escalating Doses of Lymphodepletion with or without Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Transplantation and Cellular Therapy·2025
page 1 of 16Next →

Frequent Co-authors

Robert T. OʼDonnell(9), Thomas M. Habermann(8), John H. Kehrl(7), Nancy L. Bartlett(7), Ted Wun(5), Julie M. Vose(5), Thomas F. Tedder(5), Leo I. Gordon(5), Ranjana H. Advani(5), Carol M. Richman(4), Brad S. Kahl(4), Jonathan W. Friedberg(4), Kristie A. Blum(4), Primo N. Lara(3), David R. Gandara(3), Kit S. Lam(3), Izidore S. Lossos(3), Dennis Pietronigro(3), Fangxin Hong(3), Richard I. Fisher(3)